v3.26.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Mar. 31, 2026
Dec. 31, 2025
Current Assets:    
Cash and cash equivalents $ 1,116 $ 574
Accounts receivable (net of allowance for doubtful accounts of $14 in 2026 and $12 in 2025) 1,384 1,331
Inventories (excludes inventories of $252 in 2026 and $236 in 2025 classified in Other assets) 1,373 1,406
Other current assets 1,059 1,033
Assets held for sale 0 8
Total Current Assets 4,932 4,352
Property, plant and equipment, net 1,279 1,303
Goodwill 4,153 4,153
Intangibles, net 1,099 1,130
Other assets 1,533 1,539
Noncurrent assets held for sale 0 390
Total Assets 12,996 12,867
Current Liabilities:    
Current portion of long-term debt and short-term borrowings 16 16
Trade accounts payable 983 952
Accrued and other current liabilities 1,424 1,335
Income taxes payable 77 85
Liabilities held for sale 0 2
Total Current Liabilities 2,500 2,390
Long-term debt 8,553 8,628
Deferred income taxes 56 57
Other noncurrent liabilities 984 1,008
Noncurrent liabilities held for sale 0 32
Total Liabilities 12,093 12,115
Contingencies (Note 15)
Organon & Co. Stockholders’ Equity:    
Common stock, $0.01 par value Authorized - 500,000 Issued and outstanding - 262,649 in 2026 and 260,316 in 2025 3 3
Additional paid-in capital 186 167
Retained earnings 1,253 1,109
Accumulated other comprehensive loss (539) (527)
Total Stockholders’ Equity 903 752
Total Liabilities and Stockholders’ Equity $ 12,996 $ 12,867